If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
